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Tbjective: Six years ago an endovascular program for repair of descending thoracic
neurysms was established at the University of Pennsylvania. We report on the
ypothesis that results are improving with new stent design iterations and describe
ur experience and lessons learned.
ethods: From April 1999 to March 2005, 99 patients with descending thoracic
neurysms underwent repair with a first or second-generation commercially pro-
uced endograft; 24 patients had an early-generation device, and 75 patients had a
ate-generation device. Each patient was enrolled as part of 3 distinct Phase I or
hase II Food and Drug Administration-approved clinical trials in accordance with
trict inclusion and exclusion criteria.
esults: Mean age was 73.1 years. Symptomatic aneurysms accounted for 42% of
he cohort. Mean aneurysm size was 63.7 mm (range: 30-105 mm). Twenty percent
f the patients underwent a subclavian carotid transposition or bypass preoperatively
o obtain an adequate proximal landing zone. No procedures had to be aborted.
n-hospital or 30-day mortality was 5.0%. The incidence of permanent spinal
schemia was 2%. Perioperative vascular complications requiring interposition graft,
tent repair, or patch angioplasty occurred in 27% and seemed to be less frequent in
he late-generation cohort than the early-generation cohort (22.7% vs 41.7%, re-
pectively, P  .069). At the 30-day follow-up, 23 endoleaks were detected in 22
atients (14.7% in late-generation cohort vs 45.8% in early-generation cohort, P 
001). During the follow-up period, 3 new endoleaks were detected, 3 patients died
f aortic rupture, and 10 patients underwent aneurysm-related reintervention.
aplan-Meier estimated 1, 3, and 5-year survival was 84.5%, 70.5%, and 52.4%,
espectively. Freedom from aneurysm-related event, defined as freedom from en-
oleak, aortic rupture, dissection, or any reintervention on the aorta, was 73%, 69%,
nd 64% at 1, 3, and 5 years, respectively.
onclusion: Thoracic aortic stent grafting is a safe procedure in selected patients
ith the added benefit of a low incidence of paraplegia. However, there is an incidence
f late complications and reinterventions. This risk requires further quantification
nd must be balanced against the benefits of a minimally invasive approach with low
erioperative morbidity and mortality. Results are improving as technology evolves
nd our level of experience increases. Radiologic follow-up is mandatory.
pen repair of a descending thoracic aneurysm (DTA) is still associated with
significant morbidity and mortality.1,2 Recent refinements in open tech-
nique, including extracorporeal circulation for peripheral organ preserva-
ion and multiple techniques for spinal cord protection, may improve results but are
ot applied universally. The highly invasive nature of this procedure necessitates a
rolonged recovery period. In addition, high-risk patients who were previously
enied surgical repair because of comorbidities, including but not limited to pul-
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A
CDonary, cardiac, and renal status, may become surgical
andidates if a less-invasive endovascular option was pos-
ible. For these reasons, endovascular repair is preferable.
The objectives of this article are to report on the hypoth-
sis that results are improving with new stent design itera-
ions and to describe our experience over a 6-year period.
ethods
his report analyzes 99 of 128 endografts for DTA from April 1,
999, to March 31, 2005, performed at the University of Pennsyl-
ania. Included were all patients entered in clinical trials approved
y the Food and Drug Administration (FDA). Excluded were
omemade devices, compassionate use indications, and off-label
out of trial) uses of endografts. Data were prospectively entered
nto a clinical database. All protocols and procedures were ap-
roved by the FDA, and consent was obtained from the institu-
ional review board. All patients gave informed consent before
nclusion in this study.
Early-generation devices were inserted in high-risk patients
nrolled in a Phase I study: Investigation of the TALENT Endolu-
inal Spring Stent Graft System for the Treatment of Thoracic
ortic Aneurysms in High-Risk Patients.
Late-generation devices were inserted in patients who were
perative candidates enrolled in 1 of the following Phase 2 trials:
1. Evaluation of the Medtronic AVE Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneu-
rysms: The VALOR trial
2. A Clinical Study Comparing Use of the Thoracic Excluder
Endoprosthesis to Open Surgical Repair in the Primary Treat-
ment of Descending Thoracic Aneurysms (TAG 99-01)
3. Treatment IDE for Use of the GORE TAG Thoracic Endo-
prosthesis in Subjects with Descending Thoracic Aortic
Aneurysms Requiring Surgical Repair
A surgical team consisting of a cardiac surgeon and vascular
urgeon performed all operations. Operations were performed un-
er general anesthesia in the cardiac surgery or vascular surgery
perating theatre. Recently, a fully equipped endovascular suite
as built in the main operating room. All patients recovered
ostoperatively in the cardiac surgical intensive care unit.
Use of cerebrospinal fluid drains and somatosensory evoked
otential monitoring was not standardized in this population but
volved with increasing experience. In our current management
aradigm, preoperative lumbar drains and intraoperative somato-
ensory evoked potential monitoring are used in all patients who
re considered high risk for spinal ischemia. These include the
ollowing:
● previous abdominal aortic aneurysm repair
● previous descending thoracic aortic surgery
● planned complete aortic coverage from left subclavian to
Abbreviations and Acronyms
CT  computed tomography
DTA descending thoracic aneurysm
FDA  Food and Drug Administrationceliac axis (type C, Figure 1) g
088 The Journal of Thoracic and Cardiovascular Surgery ● MaAll patients who had planned left subclavian artery coverage
nderwent preoperative elective left carotid-subclavian bypass. All
atients with DTAs were considered for both endovascular repair
nd open repair by the same surgical team. If the aneurysm profile
id not fit the inclusion/exclusion criteria of the respective trials or
atients did not consent to endovascular repair, an open repair was
onducted with the use of left-sided heart bypass.
reoperative Imaging
ll potential candidates underwent preoperative aortography or
igh-definition computed tomography (CT) scanning. CT scans
ere then digitally reformatted into 3 dimensional 1-mm cuts
sing MMS technology (Medical Metrx Solutions, West Lebanon,
H), providing a patient-specific model that assists in understand-
ng the relationships between structures and helps in accurately
esigning a stent graft system. Cerebrovascular assessment was
ased on angiographically determined vertebral artery patency. No
ttempt was made at preoperatively imaging intercostal arteries
hat may supply the spinal cord.
tatistical Analysis
ll statistical tests were 2-tailed. Student t tests, chi-square tests,
nd Fisher exact tests were conducted when appropriate to assess
ifferences between groups. Overall survival and freedom from
neurysm-related event curves were calculated by the Kaplan-
eier method. Calculations were performed using SPSS (SPSS for
indows, Version 12.0, SPSS Inc. Chicago, Ill).
esults
atient Characteristics
total of 99 patients satisfied all inclusion and exclusion
riteria between April 1, 1999, and March 31, 2005, and were
nrolled to receive an endograft; 24 patients received an
arly-generation endograft, and 75 patients received a late-
igure 1. Classification of descending thoracic aneurysms (DTAs).
escending thoracic aortic aneurysms are classified as type A,
eft subclavian artery to T6 (A); type B, midthoracic aorta to celiac
xis (B); or type C, left subclavian to celiac axis (C).eneration endograft. Patient demographics are outlined in
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A
CDable 1. There was a significantly higher incidence of chronic
bstructive pulmonary disease, peripheral vascular disease,
nd previous aortic surgery in the early-generation cohort.
neurysm Profile
etails of the aneurysm profile are depicted in Table 2.
here was no significant difference in the mean size of
neurysm, percentage of symptomatic aneurysms, and per-
entage of saccular aneurysm in the early-generation versus
ate-generation cohorts. Aneurysms were almost all exclu-
ively atherosclerotic in cause. Aortic dissections, mycotic,
nd traumatic aneurysms were not included in these trials.
neurysm location was classified as type A (left subclavian
o T6), 30%; type B (midthoracic aorta to celiac axis), 31%;
nd type C (left subclavian to celiac axis), 35% (Figure 1).
here was no significant difference in aneurysm location
etween the early and late-generation cohorts (P  .2).
arly Outcome
Perioperative mortality. Operative mortality, defined as
eath within 30 days of the procedure or during the same
ospital admission, was 5.1% (n  5) for the entire study
ABLE 1. Patient demographics
Early generation
N  24
Late gene
N  7
ean age (y) 75.62 72
ex:
Male 16 (66.7%) 41 (54.
Female 8 (33.3%) 34 (45.
AD 15 (62.5%) 31 (41.
OPD 19 (79.2%) 35 (46.
moking 21 (87.5%) 58 (77.
TN 19 (79.2%) 50 (66.
iabetes 3 (12.5%) 10 (13.
VD* 7 (29.2%) 9 (12.
enal insufficiency 4 (16.7%) 16 (21.
rior cardiac surgery 3 (12.5%) 16 (21.
revious aortic surgery 7 (29.2%) 9 (12.
AD, coronary artery disease; COPD, chronic obstructive pulmonary disea
arotid artery stenosis, abdominal aortic aneurysm, claudication, and hist
ABLE 2. Aneurysm profile
Early generation
N  24
Late genera
N  75
ymptomatic 12 (50%) 30 (40%)
accular aneurysm 7 (29.2%) 28 (37.3%
neurysm size
Mean 65.2 63.2
Range 45-99 30-105
The Journal of Thoracicopulation. There was no difference in early-generation
4.2%) versus late-generation (5.3%) cohorts (P  .9). The
auses of death were respiratory failure (1), myocardial infarc-
ion (1), sudden cardiac arrest (1), sepsis (1), and postoper-
tive paraplegia and renal failure (1) (this patient ultimately
ied of multisystem organ failure).
Procedural data. All 99 patients had successful deploy-
ent of the device, and no patients required conversion to
pen repair. The mean number of devices used per patient
as 2.62 (3.04 vs 2.49, early vs late generation, P  .07).
he left subclavian was covered in 20 cases (20.8% vs
1.3%, early vs late generation, P  .96) after a scheduled
lective carotid subclavian transposition or bypass. The site
f vascular access was the femoral artery in 68 cases, iliac
rtery in 28 cases, and infrarenal aorta in 2 cases (early vs
ate generation, P  .15). Nineteen patients had a conduit
onstructed to insert the device (20.8% vs 18.7% early
eneration vs late generation, P  .82).
Overall, 11% of patients required mechanical ventilation
ore than 24 hours (20.8% vs 8%, early vs late generation,
 .08). The incidence of renal failure was 3% (8.3% and
.3%, early vs late generation, P  .08).
Overall University of
Pennsylvania experience
N  99
P value
(early vs late generation)
73.1 .201
57 .301
42 .301
46 .07
54 .005
79 .28
69 .246
13 .916
16 .047
20 .62
19 .339
16 .047
TN, hypertension; PVD, peripheral vascular disease. *PVD as defined by
f leg ischemia requiring intervention.
Overall University of
Pennsylvania experience
N  99
P value
(early vs late generation)
42 .388
35 .466
63.68 .472ration
5
7%)
3%)
3%)
7%)
3%)
7%)
3%)
0%)
3%)
3%)
0%)
se; Htion
)30-105
and Cardiovascular Surgery ● Volume 131, Number 5 1089
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1
A
CDeurologic Complications
Spinal cord ischemia. The total incidence of spinal cord
schemia was 5.1%, with no significant difference between
arly-generation (4.2%) and late-generation (5.3%) cohorts.
here was 1 case of paraplegia, 3 cases of paraparesis, and
case of only intraoperative loss of somatosensory evoked
otentials while under general anesthesia, which was re-
ersed with blood pressure management and cerebrospinal
uid drainage. Three of the 5 patients had a full recovery,
or an incidence of permanent spinal deficit of 2%. Four of
patients with spinal ischemia had type C coverage, and 1
atient had a previous abdominal aortic aneurysm repair.
Stroke. One stroke occurred in the early-generation co-
ort, and 4 strokes occurred in the late-generation cohort
P  .675), for an overall incidence of 5%. All 5 patients
ad type A or C aortic coverage, and 3 of the 5 patients had
preoperative history of cardiovascular accident. None of
he 5 patients had the left subclavian artery covered. Two of
he 5 patients made a complete recovery with no deficit at
ischarge.
Vascular access complications. Vascular complications
ccurred in 41.7% (n  10) of the early-generation cohort
nd 22.7% (n  17) of the late-generation cohort (P 
069), for an overall incidence of 27% (n 27). Of these 27
ases, repair involved an interposition graft in 41%, a patch
ngioplasty in 33%, and a bare metal stent repair in 19%.
ate Outcome
hrough the 6-year period of this study, radiologic
ollow-up was complete in 86% of patients and vital sta-
istics data were available in 100%.
Overall survival. For the entire cohort, 24 of the 99
atients died during the 6-year follow-up. Kaplan-Meier
nalysis estimated that 1, 3, and 5-year survival was 84.5%,
0.5%, and 52.4%, respectively. Five-year survival was 45%
or the early-generation cohort and 55% for the late-generation
ohort (P  .24) Figure 2.
Freedom from aneurysm-related event. The Kaplan-
eier estimate of freedom from aneurysm-related events, as
efined by freedom from endoleak, aortic rupture, aortic
issection, or reintervention on the aorta, was 73%, 69%,
nd 64% at 1, 3, and 5 years, respectively.
Three patients had an aneurysm-related death after the
erioperative period:
● Patient 1 had an early-generation endograft. He had
an endoleak that was never successfully covered de-
spite reintervention. The patient’s aorta was tortuous
with 90-degree angles that could not be navigated by
the early-generation device. He had an aortic rupture
while he was still in the hospital after an endovascular
reintervention.
● Patient 2 had an early-generation endograft and a
tortuous aorta. He had a persistent endoleak and pre- o
090 The Journal of Thoracic and Cardiovascular Surgery ● Masented 2 years postoperatively with graft migration
and subsequently a kinked graft. He was offered open
surgery but refused; he subsequently died of aortic
rupture.
● Patient 3 had a late-generation endograft. He pre-
sented to the hospital approximately 1 month postop-
eratively with a type A dissection that started at the
proximal endograft landing zone and extended in a
retrograde fashion to the ascending aorta. He under-
went urgent open surgical repair of the type A dissec-
tion. At surgery, it was discovered that the bare spring
flares of the endograft had perforated the aortic wall.
The dissection was repaired with a total arch replace-
ment using a 4-branch graft. The distal part of the
branch graft was anastomosed to the endograft. This
patient died postoperatively of multisystem organ
failure.
ndoleaks
Early. At 30-day follow-up, 23 endoleaks were detected
n 22 patients (45.8% and 14.7%, early vs late generation,
 .001). Type I endoleaks accounted for 57% (n  13),
ype II endoleaks accounted for 26% (n  6), and type III
ndoleaks accounted for 17% (n  4). There were no type
V endoleaks observed. Of 22 patients with an endoleak, 7
ad reinterventions, 4 had an endoleak resolve spontane-
igure 2. Kaplan-Meier 5-year survival, early versus late generation.usly (3 within 6 months; resolution took 2 years in 1
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A
CDatient receiving Coumadin), 3 were lost to follow-up, and
have endoleaks that are currently ongoing and being
ollowed.
Late. A late endoleak developed in 3 patients (3%) that
as not present on the 30-day follow-up CT. One patient
nderwent successful urgent surgical intervention 3 years
fter endograft placement for a symptomatic (contained
upture) endoleak at the proximal landing zone. One patient
1 year after endograft insertion) is awaiting surgical cor-
ection at the time of this writing. One patient (1 year after
ndograft insertion) is currently undergoing workup.
Reinterventions. Ten patients (10.1%) underwent rein-
ervention on the aorta (25% and 5.3%, early vs late gen-
ration, P  .012). Of these 10 patients, 7 had a reinterven-
ion for endoleak soon after their 30-day CT scan. Two
atients required surgical reintervention on their aorta (dis-
ussed previously, 1 patient for late endoleak and 1 patient
or dissection caused by the stent graft). One patient had
ndovascular reintervention for a new aneurysm that was
ot present at the initial procedure.
Of the 7 patients who underwent reintervention for an
ndoleak on their 30-day CT, all had endovascular proce-
ures, 6 with graft extensions and 1 with a coil embolization
f a type II endoleak. Four of the 7 patients had persistent
eaks on follow-up CT despite the reintervention.
iscussion
he feasibility of endovascular repair of DTA using covered
tents was reported in 1994.3 Since then, thoracic aortic
ndografts have been used with early success in small to
oderate-sized retrospective single-center series.4-9 Six
ears ago we enrolled our first patient in an FDA-approved
horacic stent graft trial.
During the 6-year period, 99 patients received 5 different
ndograft models made by 2 manufacturers. For the purpose
f this article, 2 of these models were classified as early-
eneration devices (24 patients) and 3 of these models were
lassified as late-generation devices (75 patients) on the
asis of the mechanics of the device.
The patients in the early-generation cohort were part of a
hase I study and thus not candidates for open surgical
epair. As expected, they had a significantly higher risk
rofile as manifested by an increased incidence of chronic
bstructive pulmonary disease, peripheral vascular disease,
nd previous aortic surgery. However, aneurysm morphol-
gy, as defined by location, size, percentage who are symp-
omatic, and percentage who require preoperative carotid
ubclavian bypass/transposition, was similar between the 2
ohorts.
Our series and the series in the literature show low
erioperative mortality. Although minimally invasive, en-
ografting of DTA is not without negative perioperative
utcomes. i
The Journal of Thoracicpecific Findings of This Study
he main differences in outcomes between the early-
eneration and late-generation cohorts were noticed in the
ncidence of endoleaks, reinterventions, and vascular com-
lications. In this study, results over time and with newer
eneration devices did not improve in regard to periopera-
ive mortality, stroke, or spinal ischemia.
Endoleaks post-DTA stent grafting are a poorly un-
erstand phenomenon. In this series, 22% of patients
ere documented to have an endoleak by a radiologist at
heir first follow-up CT. The incidence of endoleaks was
arkedly higher in the early-generation versus the late-
eneration cohort (45.8% vs 14.7%, respectively, P 
001). Both cohorts had similar incidence of subclavian
ransposition, distribution of access site vessels, and aneu-
ysm size, indicating that the aortic morphology was com-
arable in the cohorts. The lower incidence of endoleaks in
he late-generation cohort likely reflects that the later gen-
ration of devices are easier to deploy at the curved arch and
ortuous distal aorta, allowing more precise proximal land-
ng zone deployment. Another reason for improved results
ith endoleaks is that with more experience we are covering
ore aorta, being more aggressive with overlapping, and
sing tapered grafts more judiciously. In addition, as our
xperience has progressed we have been more aggressive in
xing endoleaks intraoperatively and not leaving the oper-
ting theatre if there is an endoleak. This is similar to open
urgery, in which we now know that after valvular repair/
eplacement, paravalvular leaks do not improve and lead to
orse long-term outcome.
Vascular complications are sometimes underestimated
ith this minimally invasive technology. The overall inci-
ence in this series was 27% (41.7% and 22.7% in early and
ate-generation cohorts, respectively). There was a strong
rend, although this value did not reach statistical signifi-
ance (P  .069). The early-generation devices all required
ultiple exchanges, which can lead to traumatic peripheral
ascular effects. The endograft devices are inserted through
heaths that measure 20F to 25F in diameter and can cause
ccess problems in certain patients. When the femorals are
f small diameter or heavily calcified, we find it prudent to
ccess the iliac vessels through a retroperitoneal approach
ather than cannulate the femorals. In addition, consider-
tion should be given to sewing on a conduit prophylacti-
ally for marginal access anatomy. Significant ileofemoral
nd infrarenal aortic complications can occur with thoracic
ndografts. In this study, ileofemoral bypass procedures,
ngioplasty, and bare stenting were all reported as vascular
omplications. Thus, it is important to have team expertise
n this area.
Spinal cord ischemia is the most dreaded and feared
omplication of DTA repair. Early reports indicated an
ncidence of up to 30% with open surgical repair. More
and Cardiovascular Surgery ● Volume 131, Number 5 1091
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1
A
CDecent published data from 2 expert high-volume centers
hat specialize in open surgical repair of DTA report mor-
ality rates in the range of 4% to 9% and paraplegia rates of
ess than 3% for isolated DTAs.10,11 Despite these publica-
ions it is hard to judge what the true incidence of spinal
schemia is today with open repair of DTA. Most centers
nd up doing small volumes, surgical techniques are vari-
ble, there is no central registry, and undesirable outcomes
re frequently underpublished. In the first completed mul-
icenter comparative trial of endovascular versus an open
urgical repair of DTA, the incidence of spinal ischemia was
.9% in the endograft cohort and 13.8% in the open surgical
ontrol cohort.12
When endografting of DTA became a technically feasi-
le option, we hypothesized that 1 of the proposed benefits,
n addition to the minimally invasive nature, may be a
ecreased perioperative incidence of spinal ischemia. The-
retic reasons for lower spinal cord ischemia rates with an
ndovascular technique include the following:
● no period of aortic crossclamping and resultant non-
pulsatile perfusion
● fewer periods of perioperative hypotension associated
with blood loss or hemodynamic shifts
● ability to tolerate higher mean arterial pressures be-
cause there are no suture lines
● earlier awakening from general anesthesia, which al-
lows one to tailor blood pressure management to
neurologic examination
Conversely, one could postulate that an open technique
ay confer an advantage for the following reasons.
● Intercostals, which would be sacrificed with stent
grafting, can be reattached or intercostals that are not
reattached would at the very least be oversewn and not
cause spinal steal.
● The extent of aorta replaced may be greater with stent
grafting because the seal on the stent graft is better
when the landing zone is further away from the true
aneurysm.13
● The large sheath insertion required for endografting
increases the chance of injury to iliac vessels, which
supply important collaterals to the spinal cord from
the hypogastric and pelvic vascular plexus.
The incidence of spinal ischemia in this series was 5.1%,
ith no difference between the early and late-generation
ohorts. This is comparable to the incidence of 3.6% to
.5% in the published literature.6,14-16 Three of the 5 pa-
ients fully recovered by following a published paradigm for
anagement of spinal ischemia.17-19 Thus, the incidence of
ermanent spinal cord ischemia after endografting in this
eries was 2%.
The incidence of stroke was 5%. In a multicenter com-
arative trial of endografting versus open surgical repair,
e previously reported a higher incidence of stroke in
092 The Journal of Thoracic and Cardiovascular Surgery ● Maatients with subclavian-carotid transposition or bypass and
ostulated that it may be an indication of higher atheroscle-
otic burden at the level of the arch. However, in this study
one of the 5 patients with stroke underwent a subclavian-
arotid transposition or bypass preoperatively. Thus, the
ncidence and cause of stroke with endografting require
urther clarification.
Freedom from an aneurysm-related event, as defined by
reedom from any endoleak, aortic rupture, dissection, or
ortic reintervention, was 64% at 5 years. There were 3
ases of frank aortic rupture; 2 were related to endoleaks,
nd 1 was caused by an uncovered nitinol stent that ruptured
he aorta proximally and led to a retrograde dissection.
etrograde type A dissection from thoracic aortic stent
rafting has been reported in the literature.20 We now gen-
rally try to avoid the use of uncovered stents.
The Kaplan-Meier estimated 1, 3, and 5-year survival
as 84.5%, 70.5%, and 52.3%, respectively, which is con-
istent with results of thoracic endografting reported in the
iterature.6,12,20 Aneurysm-related mortality after the peri-
perative period was 3%. This indicates that patients with
horacic aortic aneurysms have complex diseases and die of
omorbidities unrelated to their thoracic aortic aneurysm.
hese patients require close follow-up in a multidisciplinary
ashion. In a thought-provoking article, Demers and col-
eagues21 at Stanford questioned whether asymptomatic pa-
ients who are deemed to be inoperable for open repair
hould have even been treated with endografting because
urvival in this group was bleak. In this study, when patients
ith symptomatic aneurysms were compared with patients
ith asymptomatic aneurysms (some of whom were deemed
inoperable”) there was no difference in survival. This topic
arrants further investigation.
onclusions/Lessons Learned
● Vascular complications do occur, but their incidence
is decreasing with new devices. Team expertise is
required to deal with them.
● The incidence of endoleaks and reinterventions is
decreasing with newer generation devices. Endoleaks
usually occur early, but as experience progresses, late
endoleaks are being seen.
● Long-term outcome of endografts in the thoracic aorta
is unknown. There is an incidence of complications
and reintervention. These grafts should be used with
caution in young patients. All patients who receive a
thoracic endograft require mandatory lifelong radio-
logic follow-up.
● As thoracic endografts receive FDA approval and
become readily available, caution needs to be exer-
cised. We agree wholeheartedly with Dr Verdant’s
comments22 when he mentioned that these operations
should be conducted in “. . . highly specialized centres
y 2006
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A
CDfor aortic surgery equipped with fully trained person-
nel and optimal methods of organ protection.”
● On the basis of these data, we can expect to see
improved results as device designs improve. These
data support a challenge to the industry to continue
development of thoracic aortic disease-specific stent
designs.
eferences
1. Hamerlijnck RP, Rutsaert RR, De Geest R, Brutel de la Riviere A,
Defauw JJ, Vermeulen FE. Surgical correction of descending thoracic
aortic aneurysms under simple aortic cross-clamping. J Vasc Surg.
1989;9:568-73.
2. Huynh TTT, Miller CC, Estrera AE, Porat EE, Safi HJ. Thoracoab-
dominal and descending thoracic aortic aneurysm surgery in patients
aged 79 years or older. J Vasc Surg. 2002;36:469-75.
3. Dake MD, Miller DC, Semba CP, et al. Transluminal placement of
endovascular stent-grafts for the treatment of descending thoracic
aortic aneurysms. N Engl J Med. 1994;331:1729-34.
4. Ramaiah V, Rodriguez-Lopez J, Diethrich EB. Endografting of the
thoracic aorta: single center experience with technical considerations.
J Card Surg. 2003;18:444-54.
5. Ehrlich M, Grabenwoeger M, Cartes-Zumelzu F, et al. Endovascular
stent graft repair for aneurysms on the descending thoracic aorta. Ann
Thorac Surg. 1998;66:19-25.
6. Ellozy SH, Carroccio A, Minor M, et al. Challenges of endovascular
tube graft repair of thoracic aortic aneurysm: midterm follow up and
lessons learned. J Vasc Surg. 2003;38:676-83.
7. Lepore V, Lonn L, Delle M, et al. Treatment of descending thoracic
aneurysms by endovascular stent grafting. J Card Surg. 2003;18:
436-43.
8. Inoue K, Iwase T, Sato M, et al. Clinical application of transluminal
endovascular graft placement for aortic aneurysms. Ann Thorac Surg.
1997;63:522-8.
9. Criado FJ, Clark NS, Barnatan MF. Stent graft repair in the aortic arch
and descending thoracic aorta: a 4-year experience. J Vasc Surg.
2002;36:1121-8.
0. Coselli JS, LeMaire SA, Conklin LD, Adams GJ. Left heart bypass
during descending thoracic aortic aneurysm repair does not reduce the
incidence of paraplegia. Ann Thorac Surg. 2004;77:1298-303.
1. Estrera AL, Rubenstein FS, Miller CC, et al. Descending thoracic
aortic aneurysm: surgical approach and treatment using the adjuncts
cerebrovascular fluid drainage and distal aortic perfusion. Ann Thorac
Surg. 2001;72:481-6.
2. Bavaria JE, Appoo JJ, Makaroun MS, et al. Endovascular stent graft-
ing versus open surgical repair of descending thoracic aortic aneu-
rysms: a multi-center comparative trial. J Thorac Cardiovasc Surg.
Submitted.
3. Bavaria JE. Invited commentary on: descending thoracic aortic aneu-
rysm: surgical approach and treatment using the adjuncts cerebrospinal
fluid drainage and distal aortic perfusion. Ann Thorac Surg. 2001;72:
486.
4. Gravereaux EC, Faries PL, Burks JA, et al. Risk of spinal cord
ischemia after endograft repair of thoracic aortic aneurysms. J Vasc
Surg. 2001;34:997-1003.
5. Mitchell RS, Miller DC, Dake MD. Stent graft repair of thoracic aortic
aneurysms. Semin Vasc Surg. 1997;10:257-71.
6. Leurs LJ, Bell R, Degrieck Y, et al. Endovascular treatment of thoracic
aortic diseases: combined experience from the EUROSTAR and
United Kingdom Thoracic Endograft registries. J Vasc Surg. 2004;40:
670-80.
7. Cheung AT, Pochettino A, Guvakov DV, et al. Safety of lumbar drains
in thoracic aortic operations performed with extracorporeal circulation.
Ann Thorac Surg. 2003;76:1190-7.
8. Cheung AT, Weiss SJ, McGarvey ML, et al. Interventions for revers-
ing delayed-onset postoperative paraplegia after thoracic aortic recon-
struction. Ann Thorac Surg. 2002;74:413-21. a
The Journal of Thoracic9. Cheung AT, Pochettino A, McGarvery ML, et al. Strategies to manage
paraplegia risk after endovascular stent repair of descending thoracic
aortic aneurysms. Ann Thorac Surg. 2005;80:1280-9.
0. Bortone AS, De Cillis E, D’Agostino D, Schinosa LLT. Endovascular
treatment of thoracic aortic disease. Four years of experience. Circu-
lation. 2004;110(suppl II):II-262-II-7.
1. Demers P, Miller DC, Mitchell RS, et al. Midterm results of endovas-
cular repair of descending thoracic aortic aneurysms with first gener-
ation stent grafts. J Thorac Cardiovasc Surg. 2004;127:664-73.
2. Verdant A. Regarding “Challenges of endovascular tube graft repair
of thoracic aortic aneurysm: midterm follow up and lessons learned.”
J Vasc Surg. 2004:39;1145.
iscussion
r. Karmy-Jones. In the interest of disclosure I need to point out
he fact that a fellow Albertan has presented this paper in no
ocumentable way has biased my review of the paper.
The authors have presented as you have heard their six-year
xperience with endograft management, specifically with athero-
clerotic thoracic aneurysms. It is significant in my mind that their
roup has in cooperation with their vascular colleagues developed
multidisciplinary treatment program that is incorporated into
heir training program for future cardiothoracic residents.
Endografts are associated with their own specific technical
omplications, notably vascular access complications, stroke and
ndoleak. The gist of this paper is that so-called newer generation
rafts, because of more flexible delivery systems and graft mate-
ial, are associated specifically with decreased complications in
ascular access sites, endoleak and improvement in late mortality.
ecause this is a technique-specific paper, my questions that start
ff the discussion, five of them, are specifically technical.
The first is, are the strokes related to their need to cover the left
ubclavian and/or are they related to wire manipulation in the
roximal descending thoracic aorta?
Dr. Appoo. That’s a very interesting question. All patients
here the left subclavian was covered had a preoperative either
arotid subclavian bypass or subclavian transposition. In previous
ork, in a multicenter looking at comparisons between open and
ndovascular repair, we had shown that 4 out of 5 patients in the
ndovascular group all had preoperative subclavian transposition
ndicating what we thought was a higher atherosclerotic burden up
t the distal arch and strokes are associated with that. But in this
tudy, none of the five patients who had a stroke actually had
reoperative subclavian transposition.
Dr. Karmy-Jones. So it’s a little unclear.
Dr. Appoo. It’s unclear. I mean we presume that was an
ndication of higher atherosclerotic burden in those patients having
hat procedure but that wasn’t the case in this situation. As to the
ire management, I’m sure that’s part of it. We are putting wires
ll the way up the arch and into the ascending aorta at times in
hese patients.
Dr. Karmy-Jones. Preoperatively, it leads into the next ques-
ion, is that, it is an important issue for developing endovascular
rograms, but how do you assess cerebral circulation preopera-
ively. Do you favor cerebral angiography or TCD?
Dr. Appoo. We use cerebral angiography to ensure patency of
oth vertebral arteries.
Dr. Karmy-Jones. I accept your argument that the newer gener-
tion grafts are more flexible, etc., but is this benefit across the board
and Cardiovascular Surgery ● Volume 131, Number 5 1093
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CDith the graft, Gore versus Medtronic, or do you have differences that
ill shape the choice in any given case? Or can you tell?
Dr. Appoo. We tried very hard in this study not to compare one
anufacturer versus another. I think these newer devices have
oth. They have improvements across and then they have specific
hings. I think with the Gore device the major advantage is that it
s a single exchange device where you don’t have to manipulate
he vascular access site again and again. The Medtronic has ad-
antages in that it does provide a larger graft, so if you have a
atient with a large aorta, even where it is supposedly normal
aliber, sometimes that is too big for the Gore device. There are
pecific benefits of each.
Dr. Karmy-Jones. Did the use of a conduit increase, decrease or
ave no effect on the incidence of vascular access complications?
Dr. Appoo. Our overall use of conduits was 19%, similar in
oth groups. Since it was similar in both groups, we can’t assume
hat it improved it but I think maybe our employment of conduits
as more judicious. y
094 The Journal of Thoracic and Cardiovascular Surgery ● MaDr. Karmy-Jones. Finally, you have noted a greater
ncidence of comorbidities, particularly COPD, prior aortic
urgery, peripheral vascular disease in the earlier group. How
s it possible to discriminate between potential selection bias
nd the benefit of the newer generations given that compar-
son?
Dr. Appoo. Inclusion/exclusion criteria were different for
ach of the three FDA studies. As we talked about, phase I
tudy was high risk. The others were high and low risk. I think
hat is part of it in terms of outcome but the comorbidities
robably play a larger role in outcome measurements such as
troke, operative mortality, and long-term outcome. I think
evice-specific outcomes, things like vascular complications
nd endoleaks, are probably irrespective of the comorbidities in
he different patient populations.
Dr. Karmy-Jones. I’d like to thank the association for
he privilege and the pleasure of reviewing this paper. Thank
ou.
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